Biotech stocks were left for dead — written off after years of brutal bear markets, failed trials, rising rates, and policy shocks. But what if the sector is quietly waking up? On this episode of In the Money with Amber Kanwar, Amber sits down with Eden Rahim, Portfolio Manager at Next Edge Capital, to unpack why one of the market’s most volatile and misunderstood sectors may be entering a new bull cycle.
This segment is brought to you by ATB Financial. With over $100 billion in assets, ATB Financial is powering possibilities for more than 843,000 financial services clients. ATB Cormark Capital Markets is a leading North American investment firm providing holistic corporate and capital markets advice and full-service financial solutions. Visit www.ATB.com/inthemoney for more information.
- Superior Formulation with Fewer Side Effects: ZUNVEYL offers better bioavailability than existing generics like Aricept and galantamine, reducing gastrointestinal issues and insomnia for improved patient compliance in treating cognitive deficits.
- Favorable Reimbursement and Low Entry Barriers: Targets Medicare-covered long-term care facilities with a 250,000-patient market; reimbursement requires only failing one of three generic treatments, making adoption straightforward.
- Explosive Revenue Potential: Launched last year with expected 100% annual revenue growth for the next five years, drawing parallels to successful reformulations like Cipher Pharmaceuticals’ acne drug that scaled to $100M in sales.
ClearPoint Neuro (CLPT)
- Innovative Drug Delivery Technology: Their device enables deep-brain delivery for gene therapies and other treatments, giving new life to drugs that previously couldn’t reach target areas effectively.
- Extensive Partnerships for Diversified Upside: Collaborations with 60 biopharma companies, including fast-track FDA programs across seven indications, provide a “call option” on successes without the full binary risk of individual trials.
- Strong Growth Trajectory: Revenues projected at $35M in 2025 and $55M in 2026, with blue-sky potential of $250M–$500M from neurology partnerships alone, targeting up to 2 million patients.
NeurAxis (NRXS)
- Proven Efficacy for Underserved Condition: The IB-Stim device, worn over the ear for monthly treatments, delivers exceptional clinical results for severe pediatric abdominal pain where other options fail.
- Top-Tier Reimbursement Support: Secured a CPT1 code (best-in-class reimbursement) and broad payer coverage from entities like Anthem (20% of lives), ensuring seamless hospital and doctor compensation.
- Massive Addressable Market: $3B opportunity in the 600,000 pediatric IBS patients alone (at ~$5,000 per treatment course), excluding the larger adult market, with low-hanging fruit in 260 children’s hospitals.
Don’t miss our next episode!
DISCLAIMERS: This text AI generated and should be checked against actual delivery. The content provided in this podcast is for informational purposes only and does not constitute financial, investment, or professional advice. The views expressed by the host and guests are their own and do not necessarily reflect the opinions of any organization or company. The host and guests may maintain positions in any securities discussed on the podcast. Always consult with a qualified financial advisor or professional before making any investment decisions.
